Items related to biologics will be added to the top of the list as they are posted on the site.
5/31/2022
May 27, 2022 Approval Letter - KYMRIAH
5/31/2022
Cellular, Tissue, and Gene Therapies Advisory Committee June 29-30, 2022 Meeting Announcement
5/26/2022
Vaccines and Related Biological Products Advisory Committee June 28, 2022 Meeting Announcement
5/26/2022
Vaccines and Related Biological Products Advisory Committee June 14-15, 2022 Meeting Announcement
5/26/2022
Vaccines and Related Biological Products Advisory Committee June 7, 2022 Meeting Announcement
5/26/2022
Annual Patient Engagement & Regenerative Medicine Meeting 2022: An FDA CBER Workshop for Patient Advocates
5/26/2022
BK210631 - Sysmex XN-10 Automated Hematology Analyzer
5/26/2022
May 20, 2022 Approval Letter - ANDEXXA
5/25/2022
Urgent Voluntary Recall: CorneaGen Cornea/ Cornea Patch Grafts; CorneaGen is voluntarily recalling Corneal Patch Grafts bearing the following product numbers: W419221004861104; W419221004861105; W419221004861106; W419221004861103
5/24/2022
May 20, 2022 Approval Letter - Anti-Human Globulin Anti-C3d FFMU, Murine Monoclonal
5/24/2022
May 20, 2022 Approval Letter - Anti-Human Globulin Anti-IgG, -C3d FFMU, Rabbit Polyclonal/Murine Monoclonal
5/24/2022
OTAT Learn
5/24/2022
May 20, 2022 Approval Letter - DG Gel 8 Direct Coombs (Anti-IgG, -C3d)
5/24/2022
May 20, 2022 Approval Letter - DG Gel 8 Direct Coombs (Anti-C3d)
5/23/2022
Blood Pressure and Pulse Donor Eligibility Requirements – Compliance Policy; Draft Guidance for Industry
5/23/2022
Compliance Policy Regarding Blood and Blood Component Donation Suitability, Donor Eligibility and Source Plasma Quarantine Hold Requirements; Draft Guidance for Industry
5/23/2022
Recommendations to Reduce the Possible Risk of Transmission of Creutzfeldt-Jakob Disease and Variant Creutzfeldt-Jakob Disease by Blood and Blood Components; Guidance for Industry
5/20/2022
CBER Vacancy: Staff Fellow/Visiting Associate - Biologist
5/19/2022
Urgent Voluntary Recall: CorneaGen Sclera / Scleral Patch Grafts; CorneaGen is voluntarily recalling the entire lot of Scleral Patch Grafts obtained from (Lot Number) W419221008338
5/19/2022
Regulatory Education for Industry (REdI) Annual Conference 2022
5/16/2022
May 12, 2022 Approval Letter - RYPLAZIM
5/16/2022
2022 Biological License Application Supplement Noteworthy Approvals
5/16/2022
2022 Biological New Drug Application (NDA) and Abbreviated New Drug Application (ANDA) Approvals
5/13/2022
HCT/P Inspections Performed in Fiscal Years 2017-2021
5/12/2022
Biologics Procedures (SOPPs) - Section 8300: Master Files
5/12/2022
May 11, 2022 Approval Letter - Flublok Quadrivalent
5/11/2022
Expiration Date Extension for 120 BIVIGAM [Immune Globulin Intravenous (Human), 10% Liquid] Lots manufactured in 2020 - 2022
5/9/2022
Guidance Agenda: Guidance Documents CBER is Planning to Publish During Calendar Year 2022
5/6/2022
eSubmitter Application History
5/6/2022
Annual Patient Engagement & Regenerative Medicine Meeting 2022: An FDA CBER Workshop for Patient Advocates
5/3/2022
Complete List of Licensed Products and Establishments
5/3/2022
Complete List of Substantially Equivalent 510(k) Device Applications
5/3/2022
Complete List of Currently Approved Premarket Approvals (PMAs)
5/3/2022
Complete List of Currently Approved NDA and ANDA Application Submissions
4/29/2022
Regulatory Education for Industry (REdI) Annual Conference 2022
4/27/2022
April 25, 2022 Approval Letter - ANTICOAGULANT SODIUM CITRATE 4% W/V SOLUTION USP - BA 125750
Content current as of:
05/31/2022